A Cautionary Tale of Etanercept Use in Patients With Toxic Epidermal Necrolysis.
Journal
Journal of burn care & research : official publication of the American Burn Association
ISSN: 1559-0488
Titre abrégé: J Burn Care Res
Pays: England
ID NLM: 101262774
Informations de publication
Date de publication:
07 05 2021
07 05 2021
Historique:
pubmed:
1
11
2020
medline:
18
1
2022
entrez:
31
10
2020
Statut:
ppublish
Résumé
Toxic epidermal necrolysis (TEN) is a severe cutaneous reaction that can be life-threatening. In the United States, there are no established guidelines for the treatment of TEN. Supportive care including fluids and supportive therapies are the current recommendations. Research surrounding TEN involves mostly case studies or small, uncontrolled studies. Recent literature describes the use of tumor necrosis factor blockers in the treatment of TEN with positive results. These case reports describe decreased time to reepithelization, hospital length of stay, and minimal side effects. Conversely, we present three fatalities after the administration of etanercept.
Identifiants
pubmed: 33128367
pii: 5945247
doi: 10.1093/jbcr/iraa194
doi:
Substances chimiques
Immunosuppressive Agents
0
Trimethoprim, Sulfamethoxazole Drug Combination
8064-90-2
Etanercept
OP401G7OJC
Lamotrigine
U3H27498KS
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
586-589Commentaires et corrections
Type : CommentIn
Informations de copyright
© The Author(s) 2020. Published by Oxford University Press on behalf of the American Burn Association. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.